We studied the effects of sildena®l on nocturnal penile erections. We prospectively evaluated 36 patients with organic or psychogenic impotence and 5 normal, potent men. All patients completed 3 sessions of consecutive nights using the RigiScan Plus device. The ®rst two nights the patients were asked to take placebo before the session and to take 50 mg of sildena®l before the third session. In the organic impotence group the use of sildena®l induced a signi®cant improvement in time of rigidity 60 ± 100%, rigidity and tumescence activity unit values and rigidity and tumescence activity unit values per hour in the tip and base. In the psychogenic impotence group it caused signi®cant improvement only in rigidity activity unit per hour in the tip. In the potent men, changes were statistically insigni®cant. Sildena®l improves nocturnal penile erectile activity in organic impotence. Our study shows that phosphodiesterase inhibitors can improve penile erections not induced by sexual stimulation.
Introduction
Four types of penile erections may be distinguished, according to the nature of the mechanism involved: by sexual stimulation; re¯ex; pharmacological; and nocturnal. The ®rst two types occur during sexual intercourse, the third one when using drugs that cause an erection in the absence of sexual stimulation (intracavernous drugs) and the fourth results from a periodic physiological mechanism.
Penile erection depends on cavernous smooth muscle relaxation. The chain of events leading to penile erection starts with sexual stimulation, which causes the release of nitric oxide from the penile vascular endothelium and cavernous nerves, with the consequent formation of cyclic guanosine monophosphate (cGMP) by guanylate cyclase. 1 The appearance of oral drugs such as phosphodiesterase inhibitors and adrenergic blockers has led to new approaches in erectile dysfunction management. Sildena®l acts by inhibiting phosphodiesterase type 5, the isoenzyme that degrades cGMP. Therefore for sildena®l to produce a clinical effect and cause erection it is necessary that cGMP be generated by some mechanism, such as an appropriate sexual stimulation.
Nocturnal penile erection monitoring by RigiScan makes it possible to obtain objective recordings of the penile erectile activity. However, to our knowledge, the only report assessing the effect of sildena®l on penile erections by RigiScan is the one by Boollel et al. 2 In this study, the authors evaluated the erectile response to sildena®l during visual sexual stimulation in a group of patients during waking, ®nding improved erectile responses under this drug. Various authors agree that sildena®l is effective only in response to sexual stimulation. 3 There are no reports on the effect of sildena®l on erections not induced by sexual stimulation, such as nocturnal penile erections.
We conducted this research to evaluate the extent to which sildena®l affects the characteristics of nocturnal penile erections in males with erectile dysfunction.
Material and methods
We studied a total of 36 men (aged 23 ± 66 y, mean age: 46.69 y) with a clinical diagnosis of erectile dysfunction for between six months and 7 y. Men were excluded if they had penile anatomical defects (such as cavernosal ®brosis or Peyronie's disease), active peptic ulcer disease, bleeding disorders, retinitis pigmentosa, major hematological, renal or hepatic abnormalities, history of stroke or recent myocardial infarction, any major psychiatric disease or treatment with nitrates or tranquilizers.
The cause of erectile dysfunction was determined by medical history, physical examination, a RigiScan Plus test, endocrine determinations (including total and bioavailable testosterone, prolactin), a test with intracavernosal injection of a vasoactive drug, blood determinations of glycemia, cholesterol, and psychological evaluation. Several patients with known risk factors of neurological damage were studied with neurophysiological tests.
On the basis of these studies the patients were classi®ed as having organic or psychogenic erectile dysfunction. 4 We also studied a group of 5 normal, potent patients (aged 26 ± 42 y) without complaints of sexual dysfunction and without risk factors of erectile dysfunction. These volunteers followed the same indications as the other group.
Erectile dysfunction was psychogenic in 17 patients (47.2%) and organic in 19 patients (52.8%). The co-existing conditions were: hypertension (14.28%), diabetes (20%), hyperlipidaemia (17.14%), low testosterone (8.33%), low bioavailable testosterone (11.42%) 5 and smoking (25.71%). According to the study protocol, nocturnal penile tumescence and rigidity testing was performed at home for three consecutive nights using the RigiScan Plus device. Sexual activity and alcohol were prohibited during the recording periods. Data from recording nights 1 and 2 were used for diagnostic purposes and for basal tumescence and rigidity values. On these two nights the patients received a placebo pill before sleep. On the third night the patients received 50 mg of sildena®l before the monitoring. Both pills, placebo and verum, had the same characteristics. At the end of each monitoring period data were analyzed with RigiScan Plus software.
For the comparative study of RigiScan measurements, because of the differences in the extension of each nocturnal record, we also used the rigidity activity unit (RAU) and tumescence activity unit (TAU) values expressed per hour. 6 Patients with one or more sessions of less than 5 h were excluded from this study.
The investigators recorded adverse effects following the use of sildena®l.
Patients signed the informed consent. The study was approved by the Ethics and Investigation Committee of the Durand Hospital.
Statistics
Mean values between ®rst and second night were used as basal condition. The t-test for paired and non-paired samples and linear regression analysis were used.
Data are expressed as mean AE standard deviation. Differences were considered statistically signi®cant at P`0.05 levels.
Results
The mean age of patients with normal rigidity measurements was 48.23 AE 11.23 y, while that of the group with abnormal rigidity measurements was 45.31 AE 11.91 y, with no signi®cant difference. Table 1 shows basal values of RigiScan parameters in both groups of patients (organic and psychogenic) and in the control group. The statistical analysis showed that all rigidity variables analyzed had signi®cantly lower values in the group with pathologic RigiScan recordings. Figure 1 shows rigidity 60 ± 100% expressed in minutes in the 3 groups evaluated. There was a signi®cant increase with sildena®l in the group with organic impotence (tip: P`0.001; base: P`0.004) and there were no changes in the other groups.
Sildena®l administration did not signi®cantly change the number of events per night in either the two patients groups or in the control group.
There was a signi®cant increase of event duration (expressed as % of session) in the group of patients with pathologic RigiScan recordings (basal: 17.9 AE 8.9 and post sildena®l: 23.4 AE 11.2, P`0.01). Table 2 shows basal and post sildena®l administration values in the group with organic impotence. There was a signi®cant increase with sildena®l Sildena®l improves nocturnal penile erections in organic impotence C Terradas et al administration both in the tip and in the base in the following parameters: RAU, TAU, RAUah and TAUah. Table 3 shows the same parameters detailed in Table 2 but for the group with psychogenic impotence. In this group we did not ®nd signi®cant changes with the use of sildena®l, except for RAUah in the tip.
The adverse effects recorded with the use of sildena®l were: headache in two cases;¯ushing in one case; and rhinitis in one case. All these effects were well tolerated and occurred the following morning. No man reported visual disturbances. One case of headache was reported with placebo.
Discussion
In 1975 Karacan reported that males between 3 and 79 years have nocturnal penile tumescence (NPT) during normal sleep, and promoted the use of this test to distinguish between organic and psychogenic impotence. 7 It is assumed that during sleep inhibiting psychological factors do not intervene, and only the patient's neurological, vascular, endocrine or tissular factors affect erection. Nevertheless, there may be exceptions to this rule, since Roose et al 8 reported that in major depression, decreased NPT may be restored with the therapeutic reversal of depression. In nocturnal penile erections, the assumption that they have the same physiological mechanism as erections induced by sexual stimulation has been questioned. The origin of the nervous system signal that induces erection is unknown. 9 The RigiScan device makes it possible to measure the erectile event duration and the rigidity. No single normality criterion has been reported for the assessment of RigiScan results as regards rigidity percentage or duration. To improve the capacity to evaluate these results, Levine and Carroll introduced 2 integrated time-intensity area measurements of RAU and TAU. Furthermore, they developed a nomogram based on the study of normal patients. 10 The assignment of a single value to RAU or TAU to express total erectile activity has been questioned. The nocturnal session may last 5 or 10 hours in Figure 1 Penile rigidity 60 ± 100% (expressed in minutes) as measured by RigiScan Plus in the three groups of patients. Karacan established that the duration of the complete penile tumescence expressed as percentage of total sleep is 32.1% in young males, 31.6% in middle-aged males and 20.6% in elderly males. 11 In our population with normal rigidity measurements (mean age 48 y), such duration was 33% and it did not change signi®cantly with the medication. Instead, in our population with abnormal rigidity measurements, the complete penile tumescence duration was 17.9% increasing signi®cantly to 23.4% with the use of sildena®l (mean age 45 y). For a possible explanation of the data obtained in this study, it should be noted that sildena®l's mode of action has been said to imply some sequential steps: (1) sexual arousal; (2) NO release from NANC neurons and from endothelium; (3) NO-activation of guanylate cyclase in the smooth muscle; (4) cGMP-mediated relaxation of the corpus cavernosum; (5) inhibition of type 5 PDE and subsequent enhancement of cGMP activity. 12 There is no sexual stimulation during nocturnal penile erections, but the other steps may take place. This could account for sildena®l's in¯u-ence on penile erection, regardless of the origin of the nervous impulse originating the erection.
The corpora cavernosa consist of a vascular bed with a signi®cant content of connective tissue. Venoocclusion requires an adequate balance between the smooth muscle and connective tissue content. Nehra et al showed that veno-occlusion was relatively ef®cient when cavernous smooth muscle to total erectile tissue ranged from 39 to 43% and relatively inef®cient when it ranged from 13 to 29%. 13 In these patients, the lack of veno-occlusion may be due to the high content of connective tissue and the consequent insuf®cient occlusion of the draining venules. Previous studies have demonstrated a signi®cant correlation between the value of cavernous oxygen tension in the¯accid state and the percent of cavernous smooth muscle ®bers.
Among the factors regulating the smooth muscle structure, transforming growth factor b1 (TGF-1) and prostaglandin E have been investigated. Both are synthesized in the smooth muscle and their expression is regulated by oxygen tension. 14 Low oxygen tension increases TGF-1, while high oxygen tension induces the synthesis of prostaglandin E 1. Oxygen tension like blood PO 2 observed in¯accidity induce TGF-b 1 sõ Ântesis and supress PGE1 expression. TGFb 1 induces corpus cavernosum ®brosis by altering connective tissue synthesis and his injection in a rabbit animal model resulted in dose-dependent decreases in percentage of corpus cavernosum smooth muscle. 15 PGE1 has been shown to inhibit the TGF-b 1 induced collagen synthesis. 16 It has been postulated that low oxygen tension induces connective tissue synthesis, while high oxygen tension would induce collagen degradation and reduce its synthesis It has been established that the nitric oxide-cyclic guanosine monophosphate system has a major role in the pathophysiology of penile erection. Hypoxemia has been postulated as a local factor that may lead to erectile dysfunction via impaired nitiric oxide synthase. In previous studies, low oxygen states inhibit nitiric oxide synthase. In previous studies, low oxygen states inhibit nitric oxide synthesis and this evidence supports the role of oxygen tension in nitric oxide mediated penile erection. Also it has been postulated that hemodynamic compromise, down regulates NOS gene expression. 1 Sexual activity and nocturnal penile erections would by physiological processes that might improve the cavernous smooth muscle oxygenation and contribute to maintaining a normal erectile response. 13 In some patients with erectile dysfunction and sleep apnea, with no nocturnal penile activity, it was possible to improve erectile function and restore nocturnal penile erections with continuous postitive airway pressure treatment. 17 In an editorial comment, Heaton has made reference to the importance that should be attached to prolonged hypoxic conditions and to the possible changes in the cGMP system under these circumstances. 18 In our study, we have observed that the time of rigidity increases 60 ± 100% in the group with organic pathology with the use of sildena®l from a basal average time of 11.9 minutes to 33 minutes in the tip and from 10.6 minutes to 21.6 minutes in the base. This represents a remarkable increase in the time during the corpora cavernosa have better oxygenation during the night and makes it possible to speculate about the changes that may occur under the daily use of this drug. Our results support a therapeutic possibility derived from the effect of sildena®l on nocturnal penile erections.
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Conclusions
Sildena®l improves nocturnal penile erectile activity in patients with organic impotence. This action could not be shown in patients with psychogenic impotence or in normal males. Given the importance attached in experimental studies to the effect of hypoxic conditions on the corpus cavernosum and the erectile function, this ®nding could be important for inducing favorable changes in these patients. Further research is required on the long-term daily nocturnal use of molecules such as sildena®l to evaluate whether they lead to changes in the cavernous smooth muscle and therefore in erectile function, through their positive effect on nocturnal penile erections.
